PREVALENCE AND ASSOCIATION OF BENIGN PROSTATIC HYPERPLASIA AND METABOLIC SYNDROME: FINDINGS FROM A CROSS-SECTIONAL STUDY

Main Article Content

Dr Mir Abid Jan
Dr Munir Khan
Dr Syed Zia Ur Rahman
Dr Kamal Ahmad
Dr Muhammad Hamza Yousuf

Keywords

‘benign prostatic hyperplasia’, ‘BPH’, ‘metabolic syndrome’, ‘lower urinary tract symptoms’, ‘LUTS’, ‘prevalence’

Abstract

Background: It is known that the main reason for discomfort of the lower part of the urinary tract in males 40 years of age and older is benign prostatic hyperplasia or BPH. Although sex steroids affect BPH, there's increasing interest in investigating the link between metabolic syndrome and urinary symptoms. Research results, however, differ; some point to a strong beneficial relationship, while others show no meaningful correlation.


Objectives: The purpose of this investigation is to identify the prevalence of metabolic syndrome in individuals with BPH and investigate any possible connections between metabolic syndrome and symptoms associated with BPH.


Methodology: Participants in this observational cross-sectional study included people 40 years of age and older with benign prostatic hyperplasia. A questionnaire-based interview was conducted to gather data from patients visiting the urology clinic at Lady Reading Hospital, Peshawar between Jan 2023 and Oct 2023. Symptoms of urination were evaluated using the “International Prostate Symptom Score” (IPSS), and metabolic syndrome was defined according to the guidelines provided by the “US National Cholesterol Education Program Adult Treatment Panel” ‘(NCEP ATPIII)’.


Results: In our cross-sectional study involving 800 individuals, we found a median age of 60 years among participants, with a majority falling within the 51-70 age group. The median Body Mass Index (BMI) was 30, and over half of the participants had a BMI between 25 and 30. Smoking prevalence was 56.25%, and the median International Prostate Symptom Score (IPSS) was 21, indicating a predominantly severe level of symptoms. A majority (62.5%) had elevated blood pressure or was on antihypertensive treatment, while 40% had fasting blood glucose levels ≥ ‘110 mg/dl’ or were on ‘drug treatment’ for raised ‘glucose’. Notably, 40% of participants had metabolic syndrome, and 60% had elevated triglycerides. The median prostate volume was 50 ml.


Conclusion: Our study sheds light on the demographic and clinical characteristics of individuals with ‘benign prostatic hyperplasia’ (BPH) and ‘metabolic syndrome’, highlighting the frequency of both conditions and their potential associations. We observed substantial connections between lower urinary tract symptoms (LUTS) intensity and the metabolic syndrome as well as various clinical parameters such as age, BMI, smoking status, and prostate volume. These findings underscore the importance of comprehensive assessment and treatment strategies for BPH patients, particularly those with concurrent metabolic syndrome, to optimize clinical outcomes and improve quality of life. More studies are warranted to elucidate the functions responsible for driving these associations and to explore targeted interventions for this patient population.

Abstract 98 | Pdf Downloads 22

References

1. Bosch, J. L., & Weiss, J. P. (2010). "The prevalence and causes of nocturia." The Journal of Urology, 184(2), 440-446.
2. Alberti, K. G., & Zimmet, P. Z. (1998). "Definition, diagnosis and classification of diabetes mellitus and its complications: Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation." Diabetic Medicine, 15(7), 539-553.
3. Eckel, R. H., Grundy, S. M., & Zimmet, P. Z. (2005). "The metabolic syndrome." The Lancet, 365(9468), 1415-1428.
4. Fang, Y., et al. (2014). "Physical activity, sedentary behaviors, and risk of metabolic syndrome: a population-based cohort study." The American Journal of Epidemiology, 179(11), 1353-1362.
5. Roehrborn, C. G., et al. (2011). "Benign Prostatic Hyperplasia: Etiology, Pathophysiology, Epidemiology, and Natural History." In Campbell-Walsh Urology, 10th ed., Vol. 4, pp. 2569-2599. Elsevier Saunders.
6. Parsons, J. K. (2007). "Benign prostatic hyperplasia and male lower urinary tract symptoms: epidemiology and risk factors." Current Bladder Dysfunction Reports, 2(4), 212-218.
7. Eckel, R. H., Grundy, S. M., & Zimmet, P. Z. (2005). "The metabolic syndrome." The Lancet, 365(9468), 1415-1428.
8. Haynes JW, Barger EV. National Cholesterol Education Program: Adult Treatment Panel III Guidelines and the 2004 Update. Hyperlipidemia Management for Primary Care: An Evidence-Based Approach. 2008:15-38.
9. Lee, S. W., & Hsu, C. (2016). "Association between lower urinary tract symptoms and metabolic syndrome in a Taiwanese population." International Journal of Urology, 23(6), 496-501.
10. Kim, S., et al. (2015). "Association between metabolic syndrome and lower urinary tract symptoms in Korean men: results from the Korean National Health and Nutrition Examination Survey." The Journal of Urology, 194(2), 442-448.
11. Gacci, M., et al. (2015). "Association between benign prostatic hyperplasia and metabolic syndrome: a systematic review and meta-analysis". BJU International, 115(1), 24-31.
12. Li, X., et al. (2019). "Prevalence and risk factors of benign prostatic hyperplasia in Shanghai community-based study population.” Aging Male," 22(1), 1-5.
13. Parsons, J. K., et al. (2018). "Metabolic syndrome increases the risk of benign prostatic enlargement.” European Urology, 73(5), 706-715.
14. Saraswat, V. A., et al. (2020). "Impact of metabolic syndrome on the prevalence of lower urinary tract symptoms in men with benign prostatic hyperplasia". International Urology and Nephrology, 52(4), 623-629.
15. Kaur, J., et al. (2017). "Smoking as a risk factor for metabolic syndrome: a meta-analysis.” Journal of Cardiovascular Nursing, 32(5), 496-501.
16. Coyne, K. S., et al. (2014). "The International Prostate Symptom Score: a method for defining severity in benign prostatic hyperplasia.” BJU International, 113(2), 170-176.
17. Roehrborn, C. G., et al. (2016). "Lower urinary tract symptoms, benign prostatic hyperplasia, metabolic syndrome and cardiovascular disease.” BJU International, 118(3), 354-365.
18. Chughtai, B., et al. (2016). "Metabolic syndrome and benign prostatic hyperplasia: an update." Current Urology Reports, 17(4), 28.
19. Chung, B. H., et al. (2018). "Association between metabolic syndrome and lower urinary tract symptoms of males in a Korean-based population.” Canadian Urological association Journal, 12(1), E1-E6.
20. Hammarsten, J., et al. (2014). "Metabolic syndrome and adipose tissue distribution in men with benign prostatic hyperplasia.” BJU International, 113(2), 303-308.
21. Choi, J. B., et al. (2017). "Association between metabolic syndrome and lower urinary tract symptoms: a community-based study.” Urology, 108, 61-66.
22. Lee, S. W., et al. (2020). "Prevalence of metabolic syndrome and its association with lower urinary tract symptoms in a Korean health screening population.” International Neurological Journal, 24(1), 44-50.
23. Kang, T. W., et al. (2019). "Metabolic syndrome is associated with increased risk of prostate cancer: a nationwide study of 26,763 patients.” Prostate cancer and Prostate Diseases, 22(2), 324-330.
24. Peng, J., et al. (2019). "Metabolic syndrome increases the risk of bladder cancer: a systematic review and meta-analysis of observational studies.” Peer J, 7, e8012.